Free Trial
OTCMKTS:AZNCF

AstraZeneca (AZNCF) Stock Price, News & Analysis

AstraZeneca logo
$131.25 -2.67 (-1.99%)
As of 01/3/2025 05:39 PM Eastern

About AstraZeneca Stock (OTCMKTS:AZNCF)

Key Stats

Today's Range
$131.00
$133.62
50-Day Range
$124.70
$149.65
52-Week Range
$118.16
$175.00
Volume
1,703 shs
Average Volume
1,452 shs
Market Capitalization
N/A
P/E Ratio
160.84
Dividend Yield
2.13%
Price Target
N/A
Consensus Rating
N/A

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
9th Percentile Overall Score

AZNCF MarketRank™: 

AstraZeneca scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for AstraZeneca.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AstraZeneca is 160.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 113.30.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AstraZeneca is 160.84, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 87.81.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 69.52%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    AstraZeneca is a leading dividend payer. It pays a dividend yield of 3.89%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    AstraZeneca does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of AstraZeneca is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about AstraZeneca's dividend.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 69.52%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    AstraZeneca has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for AstraZeneca this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, AstraZeneca insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    40.87% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AstraZeneca's insider trading history.
Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZNCF Stock News Headlines

How this >10-cent coin is going to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
AstraZeneca lacks good medicine for Chinese limbo
See More Headlines

AZNCF Stock Analysis - Frequently Asked Questions

AstraZeneca's stock was trading at $130.00 at the start of the year. Since then, AZNCF stock has increased by 1.0% and is now trading at $131.25.
View the best growth stocks for 2025 here
.

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:AZNCF
Fax
N/A
Employees
83,500
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (OTCMKTS:AZNCF) was last updated on 1/6/2025 by MarketBeat.com Staff
From Our Partners